Evotec and Immuneering to collaborate on Artificial Intelligence (“AI”) driven ligand identification for rare hereditary metabolic diseases

Combination of cutting-edge IPSC and AI technologies creates opportunity to discover novel metabolic ligands to accelerate drug discovery in rare metabolic diseases

Topics: Corporate, Evotec, Immuneering, metabolic diseases, artificial intelligence, IPSC Read More

Most Read

Posts by Topic